I-Mab Announces Upcoming Participation at May Conferences

Rhea-AI Summary

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, announced its participation in several conferences during May 2021. Key events include the HSBC 8th Annual China Conference from May 11-21, the CICC 2021 Healthcare Investment Forum on May 18, the Macquarie D.E.L.T.A.H. China Conference on May 21, and the Morgan Stanley China Summit from May 26-28. Management representatives will include Chairman Dr. Jingwu Zang and CEO Dr. Joan Huaqiong Shen. These conferences aim to provide insights into the company’s novel biologics and clinical pipeline developments.

Positive

• Participation in multiple high-profile conferences enhances visibility and engagement with investors.
• Management's involvement in discussions may boost investor confidence in I-Mab's strategic direction.

Negative

• None.

SHANGHAI and GAITHERSBURG, Md., April 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in May. Details of the conferences and management presentation are as follows:

HSBC 8th Annual China Conference (Virtual)
Management participants: Dr. Jingwu Zang, Founder, Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior Director Investor Relations

One-on-one and small group meetings: May 11-21, 2021

For more information, please contact your HSBC representative.

CICC 2021 Healthcare Investment Forum
Presentation: Tuesday, May 18, 2021 at 4:30 p.m. China Time
Presenter: Dr. Joan Huaqiong Shen, Director and Chief Executive Officer
Location: Pudong Shangri-La Hotel, Shanghai

One-on-one and small group meetings: May 18-20, 2021

Management participants: Dr. Joan Huaqiong Shen, Director and Chief Executive Officer and Ms. Leah Liu, Senior Director Investor Relations

For more information, please contact your CICC representative.

Macquarie D.E.L.T.A.H. China Conference (Virtual)
Management participants: Dr. Jingwu Zang, Founder, Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior Director Investor Relations

One-on-one and small group meetings: May 21, 2021

For more information, please contact your Macquarie representative.

Morgan Stanley China Summit (Virtual)
Management participants: Dr. Jingwu Zang, Founder, Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior Director Investor Relations

One-on-one and small group meetings: May 26-28, 2021

For more information, please contact your Morgan Stanley representative.

About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company's unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter and WeChat.

For more information, please contact:

I-Mab

Jielun Zhu, Chief Financial Officer
E-mail: jielun.zhu@i-mabbiopharma.com
Office line: +86 21 6057 8000

Gigi Feng, Chief Communications Officer
E-mail: gigi.feng@i-mabbiopharma.com
Office line: +86 21 6057 5785

Investor Inquiries:

The Piacente Group, Inc.
Emilie Wu
E-mail: emilie@thepiacentegroup.com
Office line: +86 21 6039 8363

View original content to download multimedia:http://www.prnewswire.com/news-releases/i-mab-announces-upcoming-participation-at-may-conferences-301279916.html

SOURCE I-Mab

FAQ

What conferences is I-Mab participating in during May 2021?

I-Mab will participate in the HSBC 8th Annual China Conference, the CICC 2021 Healthcare Investment Forum, the Macquarie D.E.L.T.A.H. China Conference, and the Morgan Stanley China Summit.

When is the CICC 2021 Healthcare Investment Forum?

The CICC 2021 Healthcare Investment Forum is scheduled for May 18, 2021, at 4:30 p.m. China Time.

Who will represent I-Mab at the conferences?

Management participants will include Dr. Jingwu Zang, Dr. Joan Huaqiong Shen, Mr. Jielun Zhu, and Ms. Leah Liu.

How does I-Mab's participation in conferences affect its stock IMAB?

Participation in conferences enhances investor engagement and visibility, potentially positively influencing the stock IMAB.

What is I-Mab's focus as a biopharmaceutical company?

I-Mab focuses on the discovery, development, and commercialization of novel biologics, primarily in the immuno-oncology therapeutic area.